Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15151974 | 0.85 | — | — | |
| SCHEMBL12300701 | 0.85 | — | — | |
| SCHEMBL7006520 | 0.83 | — | — | |
| SCHEMBL13788528 | 0.83 | ADRA1A (0.41) | KDM4EMAPK1HIF1ASOAT1TSHR | |
| SCHEMBL889371 | 0.83 | — | — | |
| SCHEMBL78087 | 0.83 | — | — | |
| SCHEMBL14445106 | 0.83 | SOAT1 (0.40) | KDM4EMAPK1HIF1ASOAT1TSHR | |
| SCHEMBL21423976 | 0.83 | ALDH1A1 (0.39) | KDM4EMAPK1HIF1ASOAT1TSHR | |
| SCHEMBL11168910 | 0.81 | SOAT1 (0.46) | KDM4EMAPK1HIF1ASOAT1TSHR | |
| SCHEMBL10669744 | 0.81 | ALDH1A1 (0.50) | KDM4EMAPK1HIF1ASOAT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778573-A1 | COMPOUND WITH ANTICANCER ACTIVITY | Kyowa Kirin Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-0229667-B1 | Peptidylaminodiols | ABBOTT LAB (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5214129-A | Amidation of a protected amino acid by an di-O-protected dihydroxy-containing amine and coupling with a carboxylic acid; deprotecting; renin inhibitors; hypotensive agents | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | disclosed |
| US-5091575-A | Renin inhibitor | ABBOTT LABORATORIES (US) | 1992-02-25 | — | — | US | disclosed |
| US-5032577-A | Hypotensive | ABBOTT LABORATORIES (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0295294-A4 | PEPTIDYLAMINODIOLS. | ABBOTT LAB (US) | 1990-04-10 | — | — | EP | disclosed |
| US-4845079-A | HYPOTENSIVE, RENIN INHIBITION | ABBOTT LABORATORIES | 1989-07-04 | — | — | US | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | KDM4E 3043/4885MAPK1 23/4885HIF1A 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.